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INTRODUCTION 
The liver plays a central TOre in the maintenance of-adequate 
hemostasis. Among its many functions is the synthesis and degra-
--dation of clotting factors I, II, V, VII, IX, X, XI, XII, Fletcher, and 
Fitzgerald; clotting inhibitors a-I-antitrypsin (a I-A T), 
a-2-macroglobulin (a 2-M), and antithrombin III (AT-III); and plas-
minogen. Only F VIII is an exception-both F VIIIR:Ag and F 
VIIIR:vW are synthesized in vascular endothelium, while the site 
of production of F VIII:C is unknown. When the liver suffers 
functional damage, particularly in advanced cirrhosis, clottrng 
abnormalities frequently occur, and may result in serious bleeding 
(1,3). When such a patient requires surgery, the presence and 
severity of preoperative coagulation abnormalities may lead to 
intraoperative bleeding (2). 
In liver transplantation, because the liver disease is often 
advanced and transfusion requirements are usually high, the €-va-
luation of preoperative coagulation patterns may be -of use in 
predicting blood loss, gauging severity of liver disease, and initiating 
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TABLE 11.1. Categorization of Patients 
Diagnosis No. F M Age range 
PNC (post necrotic cirrhosis) 22 8 14 18-48 
PBC (primary biliary cirrhosis) 18 18 0 36-59 
CA (carcinoma/neoplasia) 11 7 4 21-54 
SC (sclerosing cholangitis) 8 2 6 17-45 
MISC (miscellaneous) 11 3 8 25-47 
Totals 70 38 32 17-59 
therapy. We have analyzed preoperative coagulation profiles and 
categorized patients according to diagnosis. In addition, we have 
correlated data on blood product usage with preoperative coagula-
tion abnormalities and patient survival in an attempt to predict 
which patients are at risk for massive bleeding during transplanta-
tion and for early demise. 
Patient Categories 
Patients were categorized by group as shown in Table 11.1. 
The post necrotic cirrhosis (PNC) group included patients with 
chronic active hepatitis and those with a history of hepatitis B or 
nonA, nonB hepatitis. The carcinoma/neoplasia (CA) group con-
sisted of patients with a variety of malignant tumors and one with 
multiple adenomas. In the miscellaneous (MISC) category, several 
patients had fulminant hepatitis and the others had rare or com-
bined disorders that fit neither of the previous groups. 
Coagulation Parameters 
Standard coagulation tests were performed on 64 patients 
preoperatively, and a coagulation abnormality score (CAS) was 
devised by assigning one point for each definite abnormality in the 
eight different test categories shown in Table 11.2. The CAS was 
based on a slightly more narrow definition of abnormal so that 
only distinctly abnormal values would be counted. The mean CAS, 
the mean values of the coagulation tests, and the percent abnormal 
for each te!?t in each diagnostic group and for all patients are also 
shown in Table 11.2. 
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TABLE 11.3. Mean Values (U/ml) for Coagulation factors for 
Patients in Each Category and Entire Group 
Group No. 11 V VII IX X Xl XII 
PNC 20 0.33 0.35 0.27 0.43 0.56 0.44 0.65 
MISC 10 0.46 0.45 0.52 0.45 0.64 0.46 0.67 
SC 8 1.13 0.64 1.42 1.02 1.43 0.63 1.00 
PBC 16 0.95 1.00 1.00 0.90 0.95 0.76 1.07 
CA 10 0.81 1.10 0.92 1.05 0.80 1.00 1.11 
Total 64 0.68 0.68 0.74 0.73 0.81 0.63 0.87 
Normal for all factors = 0.50-1.50 U/ml 
The most frequently abnormal tests were the thrombin time 
(67%), antithrombin III (60%), and activated partial thromboplastin 
time (59%). In Table 11.3, several coagulation factors are shown to 
have been in the low normal range preoperatively. As can be seen 
in both tables, the PNC and MISC groups had more frequently 
abnormal tests than the other groups of patients. 
Intraoperative Blood Use 
Table 11.4 shows that intraoperatiye blood prod~ct usage wa's 
highest in the PNC group, followed by the SC group. The PBC and 
CA groups used significantly lower amounts probably because the 
hepatocytes are usually less abnormal in these diseases. 
TABLE 11.4. Blood Product Usage During 70 first Liver 
Transplants. Mean Values for Each Disease Category and All 
Nt'. rl 
l~rCll;D r{jfitDl1i~ R.BC FFP Pln! 
Pl\:C 22 58.0 55.0 31.3 
MISC 11 43.7 42.1 23.0 
SC 8 58.1 47.6 21.6 
PBC 18 23.0 23.4 10.9 
CA 11 32.6 28.5 11.5 
. All 70 42.8 39.9 20.5 
*Excluding the hemophiliac. 
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The mean usage for all first liver transplantations was 43 
units for red cells, 40 for FFP, 21 for platelets, and 9 for cryo-
precipitate. 
Survival Correlation 
Correlation of RBC usage and CAS with survival was signifi-
cant for the patients as a group and for the PNC group specifically. 
Additionally, the CAS correlated significantly with RBC usage as 
shown in Table 11.5. The two postoperative groups in the table 
exclude patients who died in the operating room. 
DISCUSSION 
These findings support the contention that when widespread 
parenchymal liver damage occurs, as in many of the patients in the 
PNC and MISC groups, severe clotting abnormalities result. When 
large areas of normal hepatic parenchyma remain, as in bile duct 
disease (PBC and SC) or malignancy, normal amounts of coagula-
tion factors may still be produced. 
The correlation between the degree of coagulation abnormality 
(CAS) amtRBC usage is highly significant (p = .001); in addition, 
patients who died in the operating room and had a higher mean 
CAS used more blood than those surviving the procedure. With 
these results in mind, immediate preoperative correction of coagu-
lation defects by various means may be helpful in decreasing blood 
usage intraoperatively and possibly increasing survival. Studies to 
evaluate this are presently underway. 
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